Company intelligence / Profile preview
BioCopy
Basel, Basel-Stadt, Switzerlandbiocopy.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
BioCopy has five preclinical programs: three in solid tumors (bladder, ovarian, lung cancers) starting 2024/2025 and two in blood cancer (acute myeloid leukemia) beginning in 2025/2026. Aim is to provide drug candidates for clinical evaluation within 3-4 years.
- Therapeutic areas
- OncologyHematologyImmunology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyMultispecific biotherapeutic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Genedata (software/data backbone)
Beyond the preview
Go deeper on BioCopy.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioCopy.